WALTHAM, Mass.--(BUSINESS WIRE)--NeurAxon, Inc., a developer of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that NXN-188, a novel oral selective nitric oxide synthase inhibitor and 5HT agonist in development for migraine with aura, has been selected as one of the Top 10 most promising neuroscience projects currently available for strategic partnering. This selection was determined by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
